

## Study of extended spectrum beta lactamase producing uropathogens and their antibiotic susceptibility pattern

Rajeswari Pilli<sup>1</sup>, Vamsi Chakradhar Kapaganty<sup>2,\*</sup>

Assistant Professor, Dept. of Microbiology, NRI Institute of Medical Sciences, Visakhapatnam, Andhra Pradesh, India

**\*Corresponding Author:**

Email: docchaksdegr8@gmail.com

### Abstract

**Background & Objectives:** Escherichia coli and Klebsiella pneumoniae are major uropathogenic isolates producing Extended spectrum beta lactamases (ESBL) which confer high resistance to common antibiotics. This study was done to know the antibiogram pattern of ESBL producing isolates from urine samples.

**Materials and Methods:** Culture and Antibiotic susceptibility tests (AST) were done from midstream urine samples (MSU) collected from patients. AST was done by Kirby-Bauer disc diffusion method and the isolates resistant to ceftriaxone and cefotaxime were subjected to phenotypic double disc diffusion test as per CLSI guidelines using cefotaxime (30µg) disc alone and cefotaxime plus clavulanic acid (30/10µg) combined disc for confirmation of ESBL production.

**Results:** Out of 726 urine samples, 172 showed significant growth. Among 172 isolates, most predominant isolate was Escherichia coli (81%) and then klebsiella species(10.4%). Total ESBL producers among these isolates were 68 (39.5%). Of which 63(92.6%) E.coli and 5 (7%) Klebsiella spp. These ESBL producing E.coli showed maximum resistance to Ampicillin and sensitivity to Nitrofurantoin. Similarly Klebsiella spp. showed maximum resistance to Ampicillin and sensitivity to Amikacin. These ESBL producing E.coli & Klebsiella spp. were also minimally resistant to Meropenem, about 14% and 20% respectively.

**Conclusion:** ESBL producing E.coli was high among uropathogens and most of them were highly resistant. So antibiotic sensitivity testing should be routinely done in order to prevent antibiotic resistance and treatment failure. Treatment should be followed according to the local antibiogram to specific ESBL producing isolates.

**Keywords:** ESBL, Antibiotic susceptibility, *E. coli*, cefotaxime, Meropenem, UTI.

### Introduction

Antibiotic resistance is a major problem among bacterial isolates. Escherichia coli and Klebsiella pneumoniae are the major organisms causing Urinary tract infection(UTI) in the community. Other organisms causing UTI are Proteus, Pseudomonas, Salmonella, Staphylococcus aureus, Staphylococcus saprophyticus and Enterococci.

Extended spectrum beta-lactamase (ESBL) are the result of mutations in the ubiquitous class A TEM or SHV beta-lactamases. TEM-1 accounts for the majority of beta-lactamase-mediated resistance. These are mainly produced by Escherichia coli and Klebsiella pneumoniae. They are also produced rarely by Proteus species, Pseudomonas aeruginosa and other Enterobacteriaceae.

ESBLs confer various degrees of resistance of bacteria to broad spectrum cephalosporins, aztreonam and extended spectrum penicillins. These also confer resistance to other class of antibiotics which leads to development of Multi drug resistance (MDR) organisms which are resistant to more than two classes of antibiotics. Treatment for these ESBL producing isolates is becoming a challenge to the clinicians because of multidrug resistance which can also be transferred from one bacteria to the other. Carbapenem resistance is also emerging more recently among these isolates.<sup>1</sup>

ESBLs were first reported in Germany in 1983 and subsequently increasing worldwide.<sup>2,3</sup> According to

area, hospital, patients, virulence of isolate and severity of infection prevalence of ESBL producing isolates varies. So percentage of ESBLs was different in various studies.<sup>4</sup>

The occurrence of ESBL producing organisms is rapidly changing with time. Their occurrence also varies from place to place. The endemicity of ESBL producers have resulted in outbreaks of infection in various hospitals worldwide. Antibiotics used against various ESBL producers leads to failures and increased patient mortality.<sup>5</sup>

Infection control and empiric choice of antibiotic mainly depends on the early detection of ESBLs.<sup>6</sup> This study was done to know the antibiogram pattern of ESBL producing isolates from urine samples. Proper screening of ESBL positive isolates should be done and according to the local antibiogram required antibiotic should be given.

### Materials and Methods

**Setting:** Current study was done in the Department of Microbiology, NRI Institute of Medical Sciences, sangivalasa, Visakhapatnam from 1<sup>st</sup> April to 30th September 2017.

**Specimens:** Total 726 clean voided midstream samples of urine were collected in wide mouthed sterile container and transported to the laboratory. Processing of the sample should not be delayed as urine is good nutrition medium for coliforms. Sample should be refrigerated if there is any delay.

**Inclusion criteria:** Patients with no use of antibiotics prior to the test.

**Identification of isolates:** Blood agar and Mac Conkey medium were used for culture. Loopful of urine was inoculated on these media and incubated at 37°C for 24 hours. Colonies were identified by Gram's Staining and biochemical reactions<sup>7</sup>. Motility done by hanging drop preparation.

**Antibiotic Susceptibility Testing:** Mueller Hinton Agar was used for Antibiotic Susceptibility Test which was done by Kirby Beur Disc diffusion method<sup>8</sup>. Himedia antibiotic discs used were ampicillin(10µg), amoxyclav(30µg), cefazoline(30µg), cefotaxime (30µg), ceftriaxone (30µg), ciprofloxacin 5µg, cotrimoxazole (1.25/23.75µg), gentamycin (10µg), imipenem (10µg), nitrofurantoin (300µg), norfloxacin (10µg), piperacillin tazobactam (100µg+10µg), and Meropenem (10µg).

Isolates with zone of inhibition of less than 25mm for ceftriaxone or less than 27mm for cefotaxime were tested for ESBL confirmation by Double disc diffusion method using cefotaxime (30µg) alone and cefotaxime with clavulanic acid (30µg +10µg) . Distance between the two discs should be 25mm on Mueller Hinton agar. Zone of inhibition of  $\geq$ 5mm around cefotaxime clavulanic acid compared to cefotaxime alone confirms ESBL. (Fig. 1).

**Ethical Consideration:** Approval from ethics committee was not required for this study as urine samples were routinely cultured in the laboratory.




**Fig. 1: Double disc diffusion method using cefotaxime & cefotaxime clavulanic acid**

## Results

Total 726 urine samples were collected and tested. Among them only 172(23.6%) samples were positive.

Out of 172 positives, 40 (23.2%) were males and 132 (76.7%) females. Male to female ratio is 1:2. Most predominant isolate among all isolates was *Escherichia coli* (141) and then *Klebsiella* species(18), *Enterobacter*(5), *Citrobacter*(3), *Proteus* (3) and *Pseudomonas*(2). (Table 1)

Among 172 isolates, 112 (65%) were multi drug resistant (MDR). Among these 112 MDR, 103(92%) *E.coli* and 9(8%) *Klebsiella* spp. Total ESBL producers among these isolates were 68/172 (39.5%). Of which 63 (92.6%) *E.coli* and 5 (7%) *Klebsiella* spp. (Fig. 2). Whereas Non-ESBL producers were 104/172(60.4%), of which 78(75%) *E.coli* and 13(12.5%) *Klebsiella* spp.



**Fig. 2: Distribution of E coli and Klebsiella showing ESBL positive**

Non-ESBL producing *E.coli* showed maximum resistance (73%) to Ampicillin and 55% resistance to cephalosporins and maximum sensitivity (94.8%) to Nitrofurantoin followed by Amikacin (91%) & 84.6% to Meropenem. Similarly non ESBL *Klebsiella* showed maximum resistance (84.6%) to Ampicillin, 30.7% resistance to cephalosporins and maximum sensitivity (100%) to Meropenem.

ESBL producing *E.coli* showed maximum 100% resistance to Ampicillin and 100% sensitive to Nitrofurantoin. Whereas ESBL producing *Klebsiella* species were 100% resistant to Ampicillin, Ciprofloxacin and Amoxycillin clavulanic acid and 100% sensitive to Amikacin. These ESBL producing *E.coli* & *Klebsiella* species were also minimally resistant to Carbapenems ie; Meropenem about 14% and 20% respectively. (Fig. 3)




Fig. 3: Resistance pattern of ESBL producing E. coli and Klebsiella

Table 1: Distribution of different Gram negative isolates in urine samples

Organism	Total (172)	Percentage
E.coli	141	81%
Klebsiella	18	10.4%
Enterobacter	5	2.9%
Citrobacter	3	1.7%
Proteus	3	1.7%
Pseudomonas	2	1.1%

Table 2: ESBL producing isolates according to age

Age (years)	Total no. of isolates	ESBL positive	% of ESBL positive
< 15 yrs	9	3	33.3%
15-45 yrs	93	32	34.4%
46-60 yrs	45	15	33.3%
>60 yrs	25	13	52%

## Discussion

Major risk factors for infection with ESBL producing organisms are long term antibiotic exposure, prolonged ICU stay, severe illness and instrumentation or catheterization.<sup>9</sup> Inappropriate use of antibiotics resulted in the emergence of  $\beta$ -lactamase-producing strains that are challenge to clinical therapeutics.<sup>10</sup> Considering the increasing rate of antibiotic resistance, the present study was done to know the antibiogram of ESBL producing E. coli and Klebsiella spp so that appropriate antibiotic can be given to the patient.

Male to female ratio is 1:2 correlating with Shakhya et al.<sup>11</sup> UTI is common in females because urethra is more proximal to anus so that coliforms enter and colonize urethra and also due to short length of urethra.<sup>12</sup>

65% of the isolates in our study were multi drug resistant (MDR) correlating with Hamed Ghadiri et al<sup>13</sup> (65%). One cause of the prevalence of MDR microorganisms is the production of  $\beta$ -lactamases such as ESBL.

In the current study a total of 39.5% were positive for ESBL production which was correlating with Yadav et al 40%<sup>14</sup> and nearer to kulkarni et al<sup>15</sup> 29.16%. ESBL production was highest among E.coli 92.6% followed

by Klebsiella 7.3%. High production of ESBL in E.coli was also reported by kulkarni et al.<sup>15</sup> More than 60 years age group patients showed high prevalence of ESBL production.

ESBL producing organisms degrade extended spectrum cephalosporins and monobactams and also exhibit cross-resistance to other antibiotics, such as fluoroquinolones and aminoglycosides.<sup>16</sup>

In the current study ESBL-producing E.coli and Klebsiella isolates were highly resistant to ampicillin, amoxycylav, ciprofloxacin & cotrimoxazole. This high resistance may be because of unwarranted use of antibiotics in the community. These findings correlating with SB Yoon et al.<sup>17</sup>

Resistance to ciprofloxacin in the current study was 95.0%, which is higher than the data published by SB Yoon et al<sup>17</sup> 70%. Previously fluoroquinolones is the drug of choice and most frequently used medication for UTI because of their broad spectrum activity and easy administration.<sup>18</sup> Increased resistance to these drugs occurred because of their excessive and inappropriate use.

Carbapenems, nitrofurantoin, amikacin, gentamycin and piperacillin tazobactam showed potent antibacterial activity against ESBL producing isolates.

Among these nitrofurantoin showed maximum sensitivity to E.coli and amikacin maximum sensitivity to klebsiella. Previous studies have reported no resistance in ESBL isolates to imipenem. However, our study demonstrate the occurrence of resistance to imipenem (14%) which correlates with Hamed Ghadiri et al<sup>13</sup> (10.4%). In the current study, Aminoglycosides Amikacin & gentamycin with resistance rates of 4.7% & 36% to E.coli respectively, these findings lower for amikacin and higher for gentamycin than Hamed Ghadiri et al<sup>13</sup> which showed 11% & 15% respectively.

Amikacin use in clinical practice is limited because of its renal toxicity. Imipenem should not be considered as the empiric drug of choice even it is the most effective drug as it is the drug of last resort. It should be given only in life threatening conditions otherwise it could result in more serious challenges to the healthcare system. Nitrofurantoin or gentamycin can be given as the drug of first choice.

To limit the spread of ESBL producing isolates, ESBL detection should be included in the routine laboratory practice. Continued surveillance, appropriate use of antibiotics, and implementation of strict infection control measures are recommended to decrease ESBL frequency.

## Conclusion

ESBL producing E.coli was high among uropathogens and most of them were highly resistant. So antibiotic sensitivity testing should be routinely done in order to prevent antibiotic resistance and treatment failure. Treatment should be followed according to the local antibiogram to specific ESBL producing isolates.

## References

1. Rupp ME, Fey PD: Extended spectrum  $\beta$ -lactamase (ESBL)- producing enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. *Drugs* 2003,63(4):353–365.
2. Aminzadeh Z, Sadat Kashi M, Shabani M. Bacteriuria by extended-spectrum Beta-lactamase-producing *Escherichia coli* and *Klebsiellapneumoniae*: isolates in a governmental hospital in South of Tehran, Iran. *Iran J Kidney Dis* 2008;2(4):197-200. [PMID: 19377237]
3. Khanfar HS, Bindayna KM, Senok AC, Botta GA. Extended spectrum beta-lactamases (ESBL) in *Escherichia coli* and *Klebsiellapneumoniae*: trends in the hospital and community settings. *J Infect Dev Ctries* 2009; 3(4):295-9. [PMID: 19759493]
4. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother* 2007; 59(2): 165-74. [http://dx.doi.org/10.1093/jac/dkl483] [PMID: 17158117].
5. Naiemi NA, Murk JL, Savelkoul PH, VandenbrouckeGrauls CM, Debets-Ossenkopp YJ. Extended-spectrum beta-lactamases screening agar with AmpC inhibition. *Eur J Clin Microbiol Infect Dis*. 2009;28:989-90.
6. Cohen Stuart J, Dierikx C, Al Naiemi N, Karczmarek A, Van Hoek AH, Vos P, et al. Rapid detection of TEM,

- SHV and CTX-M extended-spectrum beta-lactamases in Enterobacteriaceae using ligation-mediated amplification with microarray analysis. *J Antimicrob Chemother* 2010;65:1377-81.
7. Collee JG, Miles RS, Watt B: Tests for identification of bacteria. In Mackie and McCartney Practical Medical Microbiology. 14th edition. Edited by Collee JG, Fraser AG, Marmion BP, Simmons A. New York: Churchill Livingstone;1996:131–149
  8. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Wayne, PA: Twenty-thi. Clinical and Laboratory Standards Institute 2013.
  9. Nathisuwan S, Burgess DS, Lewis II JS, ESBLs: Epidemiology, Detection and Treatment. *Pharmacotherapy* 2001;21(8):920-928.
  10. Deshmukh DG, Damle AS, Bajaj JK, Bhakre JB, Patwardhan NS. Metallo-  $\beta$ -lactamase-producing clinical isolates from the patients of a tertiary care hospital. *J Lab Physicians*. 2011;3:93-97.
  11. Pooja Shaky, Dhiraj Shrestha, Elina Maharjan, Vijay K. Sharma and Rabin Paudyal; ESBL Production Among E. coli and *Klebsiella* spp. Causing Urinary Tract Infection: A Hospital Based Study; *The Open Microbiology Journal*, 2017,11,23-3.
  12. Forbes BA, Sahm DF, Weissfeld AS. *Bailey & Scott's Diagnostic Microbiology*. 12th ed. USA: Mosby Elsevier 2007.
  13. Hamed Ghadiri, MSc,1 Hamid Vaez, MSc,2\* Kamal Razavi-Azarkhiavi, PhD; Prevalence and Antibiotic Susceptibility Patterns of Extended-Spectrum  $\beta$ -Lactamase and Metallo- $\beta$ -Lactamase-Producing Uropathogenic *Escherichia coli* Isolates; *Lab Med Fall* 2014;45:290-294
  14. Rajesh Kumar Yadav; Extended Spectrum Beta-Lactamase Producing Organisms and their Antibiotic Resistance among Study Population: A Clinical Study; *International Journal of Contemporary Medical Research*; Volume 3 | Issue 12 | December 2016 | ICV (2015);77.83.
  15. Rugvedkulkarni, Vaishali Dohe (kongre), Dnyaneshwari Ghadge, Arvind Bhoire; A study of extended spectrum betalactamase (ESBL) producers in clinical isolates; *Medical Journal of Western India/February* 2013/ Vol 41/ Issue 1.
  16. Paterson DL, Bonomo RA; Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev* 2005;18:657–686.
  17. SB Yoon, BS Lee, KD Lee, SI Hwang, HJ Lee and ZA Han; Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital; *Spinal Cord* (2014) 52, 298–301 & 2014 International Spinal Cord Society All rights reserved 1362-4393/14.
  18. Stamm WE, Hooton TM. Management of urinary tract infections in adults. *N Engl J Med* 1993;329:1328–1334.